Projects

Nexus Pharmaceuticals’ Sterile Injectable Manufacturing Facility, Wisconsin

Nexus Pharmaceuticals, a healthcare company based in the US, plans to build a sterile injectable manufacturing facility in Kenosha County, Wisconsin, US.

Project Type

Sterile injectable manufacturing facility

Location

Pleasant Prairie, Wisconsin, US

Estimated Investment

$250m

Start of Construction

August 2019

Expand

Nexus Pharmaceuticals, a healthcare company based in the US, plans to build a sterile injectable manufacturing facility in Kenosha County, Wisconsin, US.

The facility will be used to manufacture critical-need sterile injectable drugs for therapeutic areas, including oncology, neurology and cardiology.

Nexus will invest approximately $250m in the multiple-phase manufacturing facility over a period of ten years. The Kenosha Area Business Alliance is providing financial support for the project through the Kenosha County High Impact Fund.

Construction of the $85m first phase of the plant is expected to be commenced in August 2019 and continue through 2021. Commercial production is anticipated to begin in 2022, upon receiving approval from the Food and Drug Administration (FDA).

The facility will allow the company to meet the increasing demand for high-quality and accessible generic sterile injectable drugs while reducing drug shortages.

Location of Nexus’ sterile injectable manufacturing facility

Nexus’ sterile injectable manufacturing facility will be developed on a 16-acre site located in Prairie Highlands Corporate Park in the village of Pleasant Prairie, Kenosha County.

The site is located along Interstate 94, north of Highway 165. The facility will be 30 minutes away from the company’s headquarters in Lincolnshire, Illinois.

The company purchased the land from the Village of Pleasant Prairie in July 2019. The facility is supported by Wisconsin Economic Development Corporation, The Milwaukee 7 and Kenosha Area Business Alliance.

Details of the sterile injectable manufacturing facility

The first phase will include the construction of a three-storey manufacturing plant. The building will be outfitted with the latest technology, including multiple lyophilisation, freeze-drying machines, and an advanced isolator system.

The isolator system will minimise the risk of contamination and deliver maximum product protection and sterility.

The lyophilisation machines will be used to manufacture Nexus’ current drug portfolio, as well as generic and speciality injectable drugs.

Contractors involved

Integrated Project Services (IPS), an engineering, architecture and technical consulting services company based in the US, was selected to design the new sterile injectable manufacturing facility.

Turner Construction, a US-based construction company, will provide construction management services for the facility.

Benefits of Pleasant Prairie facility

The sterile injectable manufacturing facility will create direct employment for more than 77 people in high-tech manufacturing, engineering, science, quality control and supply chain management with an average annual salary of $70,000. The project will generate between 237 and 379 direct and indirect jobs during the construction phase. The operational phase will create up to 134 indirect jobs.

The new employment opportunities will contribute up to $512,000 in annual state income tax revenue to Wisconsin, which will also support the continued growth of the pharmaceutical manufacturing industry in the region.

Marketing commentary on Nexus Pharmaceuticals

Founded in 2003, Nexus Pharmaceuticals manufactures hard-to-formulate, easy-to-use speciality and generic drugs that are less labour-intensive.

The company’s injectable drugs are currently manufactured by third-party contractors, primarily in Europe and the US. The product pipeline comprises a number of high-quality FDA-approved critical-need injectable medications in an array of therapeutic areas, including oncology, anaesthesia, endocrinology, cardiovascular and neurology.

Some of the products include Arsenic Trioxide, Dicyclomine HCL, Isoproterenol HCL, Procainamide HCL, Prochlorperazine Edisylate and Sodium Nitroprusside injections.

Related Projects